PPFIA1 and breast carcinoma: Survival data showed shorter survival for patients with PPFIA1 amplification when compared to patients with no alteration in both the HNSCC (35.81 versus 64.78 months, p = 0.0152) and breast cancer data (125.3 versus 164.3 months, p = 0.00998) (cbioportal, TCGA-data, Additional file 11: Figure S8) [21, 22].